Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

• Mink Therapeutics reported new clinical and translational data on its investigational allo-iNKT cell therapy agenT-797 at the American Thoracic Society International Conference 2026, with the case study also published in Clinical Immunology Communications.
• The sequential regimen pairing agenT-797 with ImmunityBio’s IL-15 superagonist N-803 was linked to pathogen suppression, signs of lung immune recovery, reduced inflammatory signaling, and activation of tissue repair pathways in a critically ill patient with disseminated Coccidioides infection, ARDS, and hospital-acquired Pseudomonas pneumonia.
• The patient later transitioned to comfort care due to recurrent cardiac decompensation, with investigators attributing the likely terminal mechanism to acute heart failure rather than cytokine release or infection.
• The update supports an ongoing randomized Phase 2 trial testing agenT-797 with standard of care versus placebo with standard of care in ICU patients with severe acute lung injury and acute hypoxemic respiratory failure due to severe pneumonia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201107PRIMZONEFULLFEED9724001) on May 20, 2026, and is solely responsible for the information contained therein.